

02/09/2026

Letter to confirm Extension to the Service Level Agreements (SLA) for Supervised Consumption (SC).

Forward Leeds

Dear Community Pharmacy Contractor,

Please accept this letter of communication as an update for the Service Level Agreement (SLA) which is in place between Waythrough and Pharmacy Contractors to deliver Supervised Consumption (SC) service.

The current SLA (Service Level Agreement V10.0) will have the following changes applied from 1st of July 2026 in line with discussions between the service, local commissioners and Community Pharmacy West Yorkshire:

2.4 The agreed fee to be paid per supervised dose ('per swallow') is as follows:

- *Methadone liquid (all brands) and Espranor® oral lyophilisate: £1.60*
- *Buprenorphine sub-lingual tablet (all brands): £3.40*

(previously: Methadone liquid (all brands): £1.60 Espranor® oral lyophilisate: £1.60, Buprenorphine sub-lingual tablet (all brands): £3.35)

4.10 The Prescriber Contact Form module on PharmOutcomes may be used for sending information to the service where a response is not required. It must not be used to replace direct verbal communication where there are notable safety concerns e.g., where three or more consecutive/titration doses are missed.

(previously: 'Reporting issues' module on PharmOutcomes)

Review date: 30th of June 2027.

If you do not wish to continue providing this service, please contact Forward Leeds.

Many thanks,

Barbara Zub

National Pharmacy Technician for Waythrough

barbara.zub@waythrough.org.uk / barbara.zub@nhs.net 079777 88296